TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07383506: A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Sponsor: Cogent Biosciences, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,539,384

Rescue Site Savings

+$1,005,312

Unlock Full NCT07383506 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07383506 Rescue Dossier →